{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:51:10Z","timestamp":1793321470295,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bcp.2020.114311","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T17:23:43Z","timestamp":1603992223000},"page":"114311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets"],"prefix":"10.1016","volume":"187","author":[{"given":"Kenneth A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan P.","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa E.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114311_b0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0031-6997(25)06930-3","article-title":"Purinergic nerves","volume":"24","author":"Burnstock","year":"1972","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2020.114311_b0010","doi-asserted-by":"crossref","unstructured":"G. Burnstock, B.B. Fredholm, R.A. North, A. Verkhratsky. The birth and postnatal development of purinergic signalling: Purinergic signalling: historic overview (2010) 199, 93\u2013147.","DOI":"10.1111\/j.1748-1716.2010.02114.x"},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0306-4522(76)90054-3","article-title":"Do some nerve cells release more than one transmitter?","volume":"1","author":"Burnstock","year":"1976","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2020.114311_b0020","doi-asserted-by":"crossref","unstructured":"G. Burnstock, C. Kennedy, Is there a basis for distinguishing two types of P2-purinoceptor?, Gen. Pharmacol. 16 (1985) 433\u2013440. https:\/\/doi.org\/10.1016\/0306-3623(85)90001-1.","DOI":"10.1016\/0306-3623(85)90001-1"},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0163-7258(94)00048-4","article-title":"Purinoceptors: Are there families of P2X and P2Y purinoceptors?","volume":"64","author":"Abbracchio","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.114311_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2015.12.001","article-title":"Medicinal chemistry of adenosine, P2Y and P2X receptors","volume":"104","author":"Jacobson","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.114311_b0035","doi-asserted-by":"crossref","unstructured":"S. Baraldi, P.G. Baraldi, P. Oliva, K.S. Toti, A. Ciancetta, K.A. Jacobson, A2A Adenosine Receptor: Structures, Modeling, and Medicinal Chemistry, in: P.A. Borea, K. Varani, S. Gessi, S. Merighi, F. Vincenzi (Eds.), The Adenosine Receptors, Springer International Publishing, Cham, 2018: pp. 91\u2013136. https:\/\/doi.org\/10.1007\/978-3-319-90808-3_5.","DOI":"10.1007\/978-3-319-90808-3_5"},{"key":"10.1016\/j.bcp.2020.114311_b0040","doi-asserted-by":"crossref","unstructured":"K.A. Jacobson, D.K. Tosh, Z.G. Gao, J. Yu, R.R. Suresh, H. Rao, R. Romagnoli, P.G. Baraldi, M.A. Tabrizi, Medicinal chemistry of the A3 adenosine receptor. In: The Adenosine Receptors, The Receptors, Varani, K. (ed.). Springer, 2018, 34:169\u2013198.","DOI":"10.1007\/978-3-319-90808-3_7"},{"issue":"22","key":"10.1016\/j.bcp.2020.114311_b0045","doi-asserted-by":"crossref","first-page":"9981","DOI":"10.1021\/acs.jmedchem.5b01972","article-title":"Drug-like Antagonists of P2Y Receptors\u2014From Lead Identification to Drug Development","volume":"59","author":"Conroy","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2174\/0929867321666141215093513","article-title":"Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists","volume":"22","author":"Lambertucci","year":"2015","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2020.114311_b0055","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.15005","article-title":"Update of P2Y receptor pharmacology: IUPHAR Review 27","volume":"177","author":"Jacobson","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2020.114311_b0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-642-13443-2_6","article-title":"Xanthines as adenosine receptor antagonists","author":"M\u00fcller","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0031-6997(24)01482-0","article-title":"International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits","volume":"53","author":"Khakh","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2020.114311_b0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4939-9717-6_3","article-title":"Agonists and antagonists for purinergic receptors","volume":"2041","author":"M\u00fcller","year":"2020","journal-title":"Methods Mol Biol."},{"issue":"9","key":"10.1016\/j.bcp.2020.114311_b0075","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1021\/acs.jmedchem.5b01746","article-title":"Computational Exploration of Molecular Scaffolds in Medicinal Chemistry: Miniperspective","volume":"59","author":"Hu","year":"2016","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0080","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acs.jcim.8b00532","article-title":"ADMETopt: A Web Server for ADMET Optimization in Drug Design via Scaffold Hopping","volume":"58","author":"Yang","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2020.114311_b0085","article-title":"Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5\u2019,5\u2019\u2019-P1, P4-dithio-P2, P3-chloromethylenetetraphosphate","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS ONE"},{"issue":"39","key":"10.1016\/j.bcp.2020.114311_b0090","doi-asserted-by":"crossref","first-page":"30272","DOI":"10.1074\/jbc.M001520200","article-title":"A Novel Pharmacological Approach to Treating Cardiac Ischemia: binary conjugates of a1 and a3 adenosine receptor agonists","volume":"275","author":"Jacobson","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ddr.430310308","article-title":"Structure activity relationships for derivatives of adenosine-5?-triphosphate as agonists at P2 purinoceptors: Heterogeneity within P2X and P2Y subtypes","volume":"31","author":"Burnstock","year":"1994","journal-title":"Drug Dev. Res."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0022-5193(76)90133-8","article-title":"Purinergic receptors","volume":"62","author":"Burnstock","year":"1976","journal-title":"J. Theor. Biol."},{"issue":"1-3","key":"10.1016\/j.bcp.2020.114311_b0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0165-1838(00)00151-X","article-title":"Platelet P2 receptors: from curiosity to clinical targets","volume":"81","author":"Cusack","year":"2000","journal-title":"J. Auton. Nerv. Syst."},{"key":"10.1016\/j.bcp.2020.114311_b0110","unstructured":"K.A. Jacobson, Adenosine (P1) and ATP (P2) receptors, Comprehensive Medicinal Chemistry, Pergamon Press, London, 1990: pp. 601-642."},{"key":"10.1016\/j.bcp.2020.114311_b0115","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3389\/fimmu.2019.02301","article-title":"Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets","volume":"10","author":"Vaisitti","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.bcp.2020.114311_b0120","unstructured":"Zimmermann H. History of ectonucleotidases and their role in purinergic signaling. Biochem Pharmacol. [this issue]."},{"issue":"6","key":"10.1016\/j.bcp.2020.114311_b0125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","article-title":"Adenosine Metabolism: Emerging Concepts for Cancer Therapy","volume":"36","author":"Boison","year":"2019","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bcp.2020.114311_b0130","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1021\/ed038p620","article-title":"The discovery of Germanin by Oskar Dressel and Richard Kothe","volume":"38","author":"Dressel","year":"1961","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.bcp.2020.114311_b0135","doi-asserted-by":"crossref","unstructured":"P.M. Dunn, A.G.H. Blakeley. Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens 93 (1988) 243\u2013245.","DOI":"10.1111\/j.1476-5381.1988.tb11427.x"},{"issue":"6497","key":"10.1016\/j.bcp.2020.114311_b0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/371519a0","article-title":"New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor","volume":"371","author":"Brake","year":"1994","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0014-2999(89)90370-1","article-title":"The inhibitory action of suramin on the P2-purinoceptor response in smooth muscle cells of guinea-pig taenia caeci","volume":"166","author":"Den Hertog","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0150","doi-asserted-by":"crossref","unstructured":"K. Nakazawa, K. Fujimori, A. Takanaka, K. Inoue, Reversible and selective antagonism by suramin of ATP-activated inward current in PC12 phaeochromocytoma cells 101 (1990) 224\u2013226.","DOI":"10.1111\/j.1476-5381.1990.tb12117.x"},{"key":"10.1016\/j.bcp.2020.114311_b0155","doi-asserted-by":"crossref","unstructured":"R. J. Evans, C. Lewis, G. Buell, S. Valera, R. A. North, A. Surprenant, Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2 purinoceptors), Molecular Pharmacology 48 (1995) 178\u2013183. http:\/\/molpharm.aspetjournals.org\/content\/48\/2\/178.","DOI":"10.1016\/S0026-895X(25)10232-0"},{"key":"10.1016\/j.bcp.2020.114311_b0160","doi-asserted-by":"crossref","unstructured":"G. Burnstock J.J.I. Warland. P2-purinoceptors of two subtypes in the rabbit mesenteric artery: reactive blue 2 selectively inhibits responses mediated via the P2y- but not the P2x-purinoceptor 90 (1987) 383\u2013391.","DOI":"10.1111\/j.1476-5381.1987.tb08968.x"},{"key":"10.1016\/j.bcp.2020.114311_b0165","doi-asserted-by":"crossref","unstructured":"J.L. Boyer I.E. Zohn K.A. Jacobson T.K. Harden Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors 113 (1994) 614\u2013620.","DOI":"10.1111\/j.1476-5381.1994.tb17034.x"},{"key":"10.1016\/j.bcp.2020.114311_b0170","doi-asserted-by":"crossref","unstructured":"K. Inoue K. Nakazawa M. Ohara-Imaizumi T. Obama K. Fujimori A. Takanaka Antagonism by reactive blue 2 but not by brilliant blue G of extracellular ATP-evoked responses in PC12 phaeochromocytoma cells 102 (1991) 851\u2013854.","DOI":"10.1111\/j.1476-5381.1991.tb12265.x"},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0223-5234(02)01449-6","article-title":"Constitutional isomers of Reactive Blue 2 \u2013 selective P2Y-receptor antagonists?","volume":"38","author":"Gl\u00e4nzel","year":"2003","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2020.114311_b0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1537-1891(03)00030-2","article-title":"Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors","volume":"39","author":"Brown","year":"2002","journal-title":"Vasc.Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0185","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/med.21391","article-title":"Anthraquinones As Pharmacological Tools and Drugs: anthraquinones as pharmacological tools and drugs","volume":"36","author":"Malik","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2020.114311_b0190","doi-asserted-by":"crossref","unstructured":"N. Wiedemar D.A. Hauser P. M\u00e4ser 100 Years of Suramin Antimicrob Agents Chemother 64 (2020). https:\/\/doi.org\/10.1128\/AAC.01168-19.","DOI":"10.1128\/AAC.01168-19"},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0195","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/adt.2009.0248","article-title":"A High-Throughput 1,536-Well Luminescence Assay for Glutathione S-Transferase Activity","volume":"8","author":"Yasgar","year":"2010","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.bcp.2020.114311_b0200","doi-asserted-by":"crossref","unstructured":"S.J. Coughlan, J.W. Davenport, G. Hind, Reactive blue 2 is a potent inhibitor of a thylakoid protein kinase, European Journal of Biochemistry. 197 (1991) 467\u2013471. https:\/\/doi.org\/10.1111\/j.1432-1033.1991.tb15933.x.","DOI":"10.1111\/j.1432-1033.1991.tb15933.x"},{"issue":"2-3","key":"10.1016\/j.bcp.2020.114311_b0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(92)90877-7","article-title":"PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses","volume":"217","author":"Lambrecht","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0210","doi-asserted-by":"crossref","unstructured":"A.U. Ziganshin C.H.V. Hoyle X. Bo G. Lambrecht E. Mutschler H.G. B\u00e4umert G. Burnstock PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder 110 (1993) 1491\u20131495.","DOI":"10.1111\/j.1476-5381.1993.tb13990.x"},{"key":"10.1016\/j.bcp.2020.114311_b0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1098-2299(200011)51:3<153::AID-DDR3>3.0.CO;2-X","article-title":"Inhibition of ecto-apyrase and ecto-ATPase by pyridoxal phosphate-related compounds","volume":"51","author":"Hoffmann","year":"2000","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2020.114311_b0220","article-title":"Burnstock and the legacy of the inhibitory junction potential and P2Y1 receptors","author":"King","year":"2020","journal-title":"Purinergic Signal."},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0225","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pneurobio.2012.01.009","article-title":"GPCR mediated regulation of synaptic transmission","volume":"96","author":"Betke","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2020.114311_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1207393","article-title":"P2Y Receptors in Synaptic Transmission and Plasticity: Therapeutic Potential in Cognitive Dysfunction","volume":"2016","author":"Guzman","year":"2016","journal-title":"Neural Plasticity"},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0235","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/jm00268a028","article-title":"Three new adenosine triphosphate analogs. Synthesis and effects on isolated gut","volume":"16","author":"Gough","year":"1973","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bcp.2020.114311_b0240","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/jm00076a023","article-title":"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate","volume":"36","author":"Fischer","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0245","doi-asserted-by":"crossref","unstructured":"J.L. Boyer J.W. O'Tuel B. Fischer K.A. Jacobson T.K. Harden Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2y-purinoceptors 116 (1995) 2611\u20132616.","DOI":"10.1111\/j.1476-5381.1995.tb17215.x"},{"issue":"12","key":"10.1016\/j.bcp.2020.114311_b0250","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1021\/acs.jcim.7b00528","article-title":"Demystifying P2Y 1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses","volume":"57","author":"Ciancetta","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"21","key":"10.1016\/j.bcp.2020.114311_b0255","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","article-title":"From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis","volume":"17","author":"Springthorpe","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0260","doi-asserted-by":"crossref","first-page":"129501","DOI":"10.1016\/j.bbagen.2019.129501","article-title":"Ligand binding and activation of UTP-activated G protein-coupled P2Y2 and P2Y4 receptors elucidated by mutagenesis, pharmacological and computational studies","volume":"1864","author":"Attah","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0265","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1039\/C7MD00397H","article-title":"Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y 6 receptor agonists","volume":"8","author":"Toti","year":"2017","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.bcp.2020.114311_b0270","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1073\/pnas.90.11.5113","article-title":"Expression cloning of an ATP receptor from mouse neuroblastoma cells","volume":"90","author":"Lustig","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2-3","key":"10.1016\/j.bcp.2020.114311_b0275","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(01)01401-7","article-title":"Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells","volume":"430","author":"Patel","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-3565(24)29310-1","article-title":"Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety","volume":"299","author":"Cinkilic","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.bcp.2020.114311_b0285","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1016\/j.bmc.2012.07.042","article-title":"UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety","volume":"20","author":"Ginsburg-Shmuel","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0290","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.114.095711","article-title":"Nucleotides Acting at P2Y Receptors: Connecting Structure and Function","volume":"88","author":"Jacobson","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2020.114311_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01200","article-title":"A 15-Year Study on Up4A in Cardiovascular Disease","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0300","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11302-005-0648-2","article-title":"Structure\u2013activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors","volume":"1","author":"Shaver","year":"2005","journal-title":"Purinergic Signalling"},{"key":"10.1016\/j.bcp.2020.114311_b0305","doi-asserted-by":"crossref","unstructured":"P.M. Dunn M. Liu Y. Zhong B.F. King G. Burnstock Diinosine pentaphosphate: an antagonist which discriminates between recombinant P2X 3 and P2X 2\/3 receptors and between two P2X receptors in rat sensory neurones : Selective antagonism of P2X 3 receptors by Ip 5 I 130 (2000) 1378\u20131384.","DOI":"10.1038\/sj.bjp.0703404"},{"key":"10.1016\/j.bcp.2020.114311_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00222","article-title":"P2 receptors as therapeutic targets in the salivary gland: from physiology to dysfunction","volume":"11","author":"Khalafalla","year":"2020","journal-title":"Front Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18240\/ijo.2019.10.06","article-title":"Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome","volume":"12","author":"Kang","year":"2019","journal-title":"Int J Ophthalmol."},{"key":"10.1016\/j.bcp.2020.114311_b0320","doi-asserted-by":"crossref","unstructured":"M.A. Battistone A.C. Mendelsohn R.G. Spallanzani A.S. Allegretti R.N. Liberman J. Sesma S. Kalim S.M. Wall J.V. Bonventre E.R. Lazarowski D. Brown S. Breton Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice 130 (2020) 3734\u20133749 https:\/\/www.jci.org\/articles\/view\/134791 https:\/\/www.jci.org\/articles\/view\/134791\/sd\/1.","DOI":"10.1172\/JCI134791"},{"issue":"17","key":"10.1016\/j.bcp.2020.114311_b0325","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1021\/acs.jmedchem.0c00745","article-title":"Exploration of Alternative Scaffolds for P2Y14 Receptor Antagonists Containing a Biaryl Core","volume":"63","author":"Jung","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0330","doi-asserted-by":"crossref","unstructured":"Illes, P., M\u00fcller, C.E., Jacobson, K.A., Grutter, T., Nicke, A., Fountain, S.J., Kennedy, C., Schmalzing, G., Jarvis, M.F., Stojilkovic, S.S., King, B.F., Di Virgilio, F. Update of P2X receptor properties and their pharmacology: IUPHAR Review: x, Br. J. Pharmacol., 2020, in press, https:\/\/doi.org\/10.1111\/bph.15299.","DOI":"10.1111\/bph.15299"},{"key":"10.1016\/j.bcp.2020.114311_b0335","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/jpet.109.157750","volume":"332","author":"Meis","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114311_b0340","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11302-019-09663-4","article-title":"Profiling of a suramin-derived compound library at recombinant human P2Y receptors identifies NF272 as a competitive but non-selective P2Y2 receptor antagonist","volume":"15","author":"Brockmann","year":"2019","journal-title":"Purinergic Signalling"},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0345","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1124\/mol.110.068700","article-title":"Molecular Determinants of Potent P2X2 Antagonism Identified by Functional Analysis, Mutagenesis, and Homology Docking","volume":"79","author":"Wolf","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2020.114311_b0350","doi-asserted-by":"crossref","first-page":"111789","DOI":"10.1016\/j.ejmech.2019.111789","article-title":"Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y2 and GPR17","volume":"186","author":"Pillaiyar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0355","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ejmech.2005.07.007","article-title":"Structure-activity relationship of novel P2-receptor antagonists structurally related to Reactive Blue 2","volume":"40","author":"Gl\u00e4nzel","year":"2005","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0360","doi-asserted-by":"crossref","unstructured":"Y. Baqi C.E. M\u00fcller Convergent Synthesis of the Potent P2Y Receptor Antagonist MG 50-3-1 Based on a Regioselective Ullmann Coupling Reaction Molecules 17 (2012) 2599\u20132615 10.3390\/molecules17032599 http:\/\/www.mdpi.com\/1420-3049\/17\/3\/2599.","DOI":"10.3390\/molecules17032599"},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bmcl.2007.10.082","article-title":"Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists","volume":"18","author":"Weyler","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bcp.2020.114311_b0370","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/ol070102v","article-title":"Rapid and efficient microwave-assisted copper(0)-catalyzed Ullmann coupling reaction: general access to anilinoanthraquinone derivatives","volume":"9","author":"Baqi","year":"2007","journal-title":"Org Lett."},{"key":"10.1016\/j.bcp.2020.114311_b0375","doi-asserted-by":"crossref","unstructured":"Baqi Y, M\u00fcller CE. Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. Nat Protoc. 2010, 5(5):945\u2013953. doi: 10.1038\/nprot.2010.63. Epub 2010 Apr 29.","DOI":"10.1038\/nprot.2010.63"},{"issue":"12","key":"10.1016\/j.bcp.2020.114311_b0380","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/jm9003297","article-title":"High-Affinity, Non-Nucleotide-Derived Competitive Antagonists of Platelet P2Y 12 Receptors","volume":"52","author":"Baqi","year":"2009","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0385","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1124\/jpet.109.156687","article-title":"Interaction of New, Very Potent Non-Nucleotide Antagonists with Arg256 of the Human Platelet P2Y 12 Receptor","volume":"331","author":"Hoffmann","year":"2009","journal-title":"J Pharmacol Exp. Ther."},{"issue":"100","key":"10.1016\/j.bcp.2020.114311_b0390","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nbd.2014.06.011","article-title":"Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents","volume":"70","author":"Horv\u00e1th","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.bcp.2020.114311_b0395","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10822-015-9858-z","article-title":"Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information","volume":"29","author":"Paoletta","year":"2015","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"7","key":"10.1016\/j.bcp.2020.114311_b0400","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1021\/acs.jmedchem.7b00030","article-title":"Development of Potent and Selective Antagonists for the UTP-Activated P2Y 4 Receptor","volume":"60","author":"Rafehi","year":"2017","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2020.114311_b0405","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1021\/jm801442p","article-title":"Key Determinants of Nucleotide-Activated G Protein-Coupled P2Y 2 Receptor Function Revealed by Chemical and Pharmacological Experiments, Mutagenesis and Homology Modeling","volume":"52","author":"Hillmann","year":"2009","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2020.114311_b0410","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1021\/acs.jmedchem.7b00854","article-title":"Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y 2 Receptor","volume":"60","author":"Rafehi","year":"2017","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0415","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm1012193","article-title":"Discovery of Potent Competitive Antagonists and Positive Modulators of the P2X2 Receptor","volume":"54","author":"Baqi","year":"2011","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/j.bcp.2020.114311_b0420","doi-asserted-by":"crossref","first-page":"12820","DOI":"10.1074\/jbc.RA118.003737","article-title":"Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region","volume":"293","author":"Huo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0425","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ddr.10145","article-title":"Evidence for the recognition of non-nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor : non-nucleotide antagonists","volume":"57","author":"Guo","year":"2002","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0430","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/jm9904203","article-title":"Structure\u2212Activity Relationships of Pyridoxal Phosphate Derivatives as Potent and Selective Antagonists of P2X 1 Receptors","volume":"44","author":"Kim","year":"2001","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2020.114311_b0435","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/acschemneuro.6b00401","article-title":"Discovery of Potent Antiallodynic Agents for Neuropathic Pain Targeting P2X3 Receptors","volume":"8","author":"Jung","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0440","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ddr.1197","article-title":"Actions of a series of PPADS analogs at P2X1 and P2X3 receptors","volume":"53","author":"Brown","year":"2001","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2020.114311_b0445","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1021\/jm980183o","article-title":"A pyridoxine cyclic-phosphate and its 6-arylazo-derivative selectively potentiate and antagonize activation of P2X1 receptors","volume":"41","author":"Jacobson","year":"1998","journal-title":"J. Med. Chem."},{"issue":"1-3","key":"10.1016\/j.bcp.2020.114311_b0450","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0165-1838(00)00128-4","article-title":"In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X2 receptors","volume":"81","author":"Jacobson","year":"2000","journal-title":"J. Auton. Nerv. Syst."},{"issue":"9","key":"10.1016\/j.bcp.2020.114311_b0455","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.bcp.2004.01.011","article-title":"Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors","volume":"67","author":"Mamedova","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2020.114311_b0460","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1074\/jbc.M301734200","article-title":"Agonist Versus Antagonist Action of ATP at the P2Y 4 Receptor Is Determined by the Second Extracellular Loop","volume":"279","author":"Herold","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0465","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1021\/jm010538v","article-title":"Adenine nucleotides analogues locked in a Northern methanocarba conformation: Enhanced stability and potency as P2Y1 receptor agonists","volume":"45","author":"Ravi","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0470","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/jm030127+","article-title":"2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a Northern conformation: Enhanced potency as P2Y1 receptor antagonists","volume":"46","author":"Kim","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0475","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1021\/jm010082h","article-title":"Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: Structure activity relationships and receptor docking","volume":"44","author":"Kim","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0480","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fnmol.2019.00183","article-title":"P2X7 interactions and signaling \u2013 making head or tail of it","volume":"12","author":"Kopp","year":"2019","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0485","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1021\/acsmedchemlett.8b00524","article-title":"Investigation on 2\u2032,3\u2032- O -Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists","volume":"10","author":"Dal Ben","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2020.114311_b0490","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.1016\/S0021-9258(18)53082-9","article-title":"An irreversible inhibitor of the macrophage purinergic P2Z receptor","volume":"268","author":"Murgia","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"5262","key":"10.1016\/j.bcp.2020.114311_b0495","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.272.5262.735","article-title":"The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7)","volume":"272","author":"Surprenant","year":"1996","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bcp.2020.114311_b0500","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0026-895X(24)13265-8","article-title":"Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2\/3 receptors","volume":"53","author":"Virginio","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0505","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00058","article-title":"The molecular determinants of small-molecule ligand binding at P2X receptors","volume":"9","author":"Pasqualetto","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0510","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcp.2016.11.016","article-title":"Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies","volume":"125","author":"Abdelrahman","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0515","doi-asserted-by":"crossref","unstructured":"T. Hiratsuka Fluorescent and colored trinitrophenylated analogs of ATP and GTP: Fluorescent nucleotides, TNP-ATP and TNP-GTP 270 (2003) 3479\u20133485.","DOI":"10.1046\/j.1432-1033.2003.03748.x"},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0520","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-5793(87)80146-1","article-title":"N 6-Substituted 9-methyladenines: A new class of adenosine receptor antagonists","volume":"215","author":"Ukena","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2020.114311_b0525","unstructured":"Rosentreter U, Henning R, Bauser M, Kr\u00e4mer T, Vaupel A, H\u00fcbsch W, Dembowsky K, Salcher-Schrauf-St\u00e4tter O, Stasch JP, Krahn T and Perzborn E (2001) inventors, Bayer, assignee. Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands. WO Patent 2001\/025210."},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0530","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/jpet.113.210849","article-title":"BAY60-6583 Acts as a Partial Agonist at Adenosine A 2B Receptors","volume":"349","author":"Hinz","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.bcp.2020.114311_b0535","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11302-015-9460-9","article-title":"Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors","volume":"11","author":"Alnouri","year":"2015","journal-title":"Purinergic Signalling"},{"key":"10.1016\/j.bcp.2020.114311_b0540","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cmdc.201700151","article-title":"Neladenoson bialanate hydrochloride: A prodrug of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases","volume":"12","author":"Meibom","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2020.114311_b0545","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0026-895X(25)09561-6","article-title":"Identification of competitive antagonists of the P2Y1 receptor","volume":"50","author":"Boyer","year":"1996","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0550","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/jm970433l","article-title":"Deoxyadenosine Bisphosphate Derivatives as Potent Antagonists at P2Y 1 Receptors","volume":"41","author":"Camaioni","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0555","doi-asserted-by":"crossref","unstructured":"Burnstock G. Purinergic Signalling: Therapeutic Developments. Front Pharmacol. 2017, 8:661. doi: 10.3389\/fphar.2017.00661.","DOI":"10.3389\/fphar.2017.00661"},{"issue":"6548","key":"10.1016\/j.bcp.2020.114311_b0560","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/377428a0","article-title":"A P2X purinoceptor expressed by a subset of sensory neurons","volume":"377","author":"Chen","year":"1995","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0565","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2008.06.067","article-title":"ATP-gated P2X cation-channels","volume":"56","author":"Jarvis","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.114311_b0570","unstructured":"di Virgilio, F., Jacobson, K.A., Williams, M. Geoffrey Burnstock \u2013 An accidental pharmacologist. Biochem. Pharmacol., in press."},{"issue":"S1","key":"10.1016\/j.bcp.2020.114311_b0575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11302-011-9271-6","article-title":"In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization","volume":"8","author":"Ford","year":"2012","journal-title":"Purinergic Signalling"},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0580","doi-asserted-by":"crossref","first-page":"1900439","DOI":"10.1183\/13993003.00439-2019","article-title":"The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study","volume":"54","author":"Morice","year":"2019","journal-title":"Eur. Resp. J."},{"issue":"19","key":"10.1016\/j.bcp.2020.114311_b0585","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1073\/pnas.1800907115","article-title":"Druggable negative allosteric site of P2X3 receptors","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2020.114311_b0590","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","article-title":"BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration","volume":"56","author":"Garceau","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.114311_b0595","doi-asserted-by":"crossref","unstructured":"A Morice, J Smith, L McGarvey, S. Birring, SM Parker, A Turner, I Gashaw, L Fels, S Klein, K Francke, C Friedrich. Safety and efficacy of BAY 1817080, a P2X3 receptor antagonist, in patients with refractory chronic cough (RCC), American Thoracic Society 2020 International Conference, May 15-20, 2020, Philadelphia, PA, DOI: 10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A7648.","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A7648"},{"key":"10.1016\/j.bcp.2020.114311_b0600","unstructured":"Bellus chokes in chronic cough, https:\/\/www.evaluate.com\/vantage\/articles\/news\/trial-results\/bellus-chokes-chronic-cough, accessed Oct. 5, 2020."},{"issue":"5","key":"10.1016\/j.bcp.2020.114311_b0605","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bmcl.2019.01.039","article-title":"Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds","volume":"29","author":"Tobinaga","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2020.114311_b0610","first-page":"RCT452","article-title":"Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough","volume":"54","author":"Niimi","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.bcp.2020.114311_b0615","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/j.pain.0000000000001857","article-title":"Treatment of chronic neuropathic pain: purine receptor modulation","volume":"161","author":"Jacobson","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2020.114311_b0620","doi-asserted-by":"crossref","first-page":"113308","DOI":"10.1016\/j.expneurol.2020.113308","article-title":"Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke","volume":"329","author":"Srivastava","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2020.114311_b0625","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmch.2019.11.002","article-title":"P2X7 receptor antagonists for the treatment of systemic inflammatory disorders","volume":"59","author":"Gelin","year":"2020","journal-title":"Prog. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0630","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41386-019-0502-9","article-title":"Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders","volume":"45","author":"Bhattacharya","year":"2020","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0635","unstructured":"Jarvis MF, Geoffery Burnstock\u2019s influence on the evolution of P2X3 receptor pharmacology. Purinergic Signal., submitted."},{"issue":"7","key":"10.1016\/j.bcp.2020.114311_b0640","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/MIB.0000000000000047","article-title":"Potential for Developing Purinergic Drugs for Gastrointestinal Diseases:","volume":"20","author":"Ochoa-Cortes","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"10.1016\/j.bcp.2020.114311_b0645","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1021\/acs.jmedchem.9b00584","article-title":"Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease","volume":"63","author":"Homerin","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0650","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2018.09.021","article-title":"Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery","volume":"24","author":"Baqi","year":"2019","journal-title":"Drug Discovery Today"},{"issue":"7498","key":"10.1016\/j.bcp.2020.114311_b0655","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.bcp.2020.114311_b0660","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1021\/jm5006226","article-title":"Discovery of 4-Aryl-7-Hydroxyindoline-Based P2Y 1 Antagonists as Novel Antiplatelet Agents","volume":"57","author":"Yang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0665","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55194-8","article-title":"Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent","volume":"9","author":"Le","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bcp.2020.114311_b0670","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/jm00345a001","article-title":"Adenosine receptors: Targets for future drugs","volume":"25","author":"Daly","year":"1982","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0675","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ddr.10197","article-title":"Robert Berne: His place in the history of purine research","volume":"58","author":"Olsson","year":"2003","journal-title":"Drug Dev. Res."},{"issue":"5","key":"10.1016\/j.bcp.2020.114311_b0680","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"M\u00fcller","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"issue":"6","key":"10.1016\/j.bcp.2020.114311_b0685","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1139\/y80-110","article-title":"Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists","volume":"58","author":"Bruns","year":"1980","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114311_b0690","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Frontiers Cell. Neurosci."},{"key":"10.1016\/j.bcp.2020.114311_b0695","doi-asserted-by":"crossref","unstructured":"Jacobson, K.A., Gao, Z.G., Matricon, P., Eddy, M.T., Carlsson, J. A2A adenosine receptor antagonists: From caffeine to selective non-xanthines. Br. J. Pharmacol., in press, DOI: 10.1111\/bph.15103.","DOI":"10.1111\/bph.15103"},{"issue":"5","key":"10.1016\/j.bcp.2020.114311_b0700","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/jm201376w","article-title":"Discovery of 1,2,4-Triazine Derivatives as Adenosine A 2A Antagonists using Structure Based Drug Design","volume":"55","author":"Congreve","year":"2012","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0705","doi-asserted-by":"crossref","first-page":"e000417","DOI":"10.1136\/jitc-2019-000417","article-title":"Small molecule AZD4635 inhibitor of A 2A R signaling rescues immune cell function including CD103 + dendritic cells enhancing anti-tumor immunity","volume":"8","author":"Borodovsky","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bcp.2020.114311_b0710","doi-asserted-by":"crossref","unstructured":"Dal Ben Lambertucci Buccioni Mart\u00ed Navia Marucci Spinaci Volpini Non-Nucleoside Agonists of the Adenosine Receptors: An Overview Pharmaceuticals 12(4) (2019), 150. https:\/\/doi.org\/10.3390\/ph12040150.","DOI":"10.3390\/ph12040150"},{"issue":"8","key":"10.1016\/j.bcp.2020.114311_b0715","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1021\/acs.jmedchem.0c00235","article-title":"Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A 3 Adenosine Receptors: Affinity Enhancement by N6 -(2-Phenylethyl) Substitution","volume":"63","author":"Tosh","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0720","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejmech.2018.03.067","article-title":"New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases","volume":"151","author":"Lambertucci","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2020.114311_b0725","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/jm00169a015","article-title":"2-(Arylalkylamino)adenosin-5\u2019-uronamides: A New Class of Highly Selective Adenosine A2 Receptor Ligands","volume":"33","author":"Hutchison","year":"1990","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2020.114311_b0730","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1021\/jm061278q","article-title":"Structure\u2212Activity Relationships of 2, N6 ,5\u2018-Substituted Adenosine Derivatives with Potent Activity at the A 2B Adenosine Receptor","volume":"50","author":"Adachi","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0735","doi-asserted-by":"crossref","DOI":"10.2174\/092986711795328391","article-title":"The importance of alkynyl chain presence for the activity of adenine nucleosides\/nucleotides on purinergic receptors","volume":"18","author":"Dal Ben","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0740","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1021\/acschembio.6b00357","article-title":"Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists","volume":"11","author":"Rodr\u00edguez","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0745","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.bcp.2004.06.011","article-title":"2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors","volume":"68","author":"Gao","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0750","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.120.000004","article-title":"Chronic Morphine-Induced Changes in Signaling at the A 3 Adenosine Receptor Contribute to Morphine-Induced Hyperalgesia, Tolerance, and Withdrawal","volume":"374","author":"Doyle","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114311_b0755","doi-asserted-by":"crossref","unstructured":"Chang LC, von Frijtag Drabbe K\u00fcnzel JK, Mulder-Krieger T, et al. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.J Med Chem. 2005;48(6):2045\u20132053. doi:10.1021\/jm049597+.","DOI":"10.1021\/jm049597+"},{"key":"10.1016\/j.bcp.2020.114311_b0760","doi-asserted-by":"crossref","unstructured":"Lane, R., Klein Herenbrink, C., van Western, G. J. P., Spoorendonk, J. A., Hoffmann, C., IJzerman, A. P. (2012). A novel non-ribose agonist, LUF5834, engages distinct residues from that of adenosine-like ligands to activate the adenosine A2A receptor. Mol. Pharmacol. 81(3), 475\u2013487. \\ https:\/\/doi.org\/10.1124\/mol.111.07593.","DOI":"10.1124\/mol.111.075937"},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0765","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/bi3012065","article-title":"Ligand-Specific Binding and Activation of the Human Adenosine A 2B Receptor","volume":"52","author":"Thimm","year":"2013","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.bcp.2020.114311_b0770","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/0006-2952(87)90056-6","article-title":"Molecular probes for extracellular adenosine receptors","volume":"36","author":"Jacobson","year":"1987","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2020.114311_b0775","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/jm990421v","article-title":"Anilide Derivatives of an 8-Phenylxanthine Carboxylic Congener Are Highly Potent and Selective Antagonists at Human A 2B Adenosine Receptors","volume":"43","author":"Kim","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0780","doi-asserted-by":"crossref","unstructured":"Hayallah AM, Sandoval-Ram\u00edrez J, Reith U, Schobert U, Preiss B, Schumacher B, Daly JW, M\u00fcller CE. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J Med Chem. 2002 Mar 28;45(7):1500\u20131510. doi: 10.1021\/jm011049y.","DOI":"10.1021\/jm011049y"},{"issue":"13","key":"10.1016\/j.bcp.2020.114311_b0785","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1021\/jm900413e","article-title":"1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A 2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity","volume":"52","author":"Borrmann","year":"2009","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114311_b0790","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.bcp.2020.114311_b0795","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cmdc.200800434","article-title":"Adenosine A2A receptor antagonists: New 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease","volume":"4","author":"Volpini","year":"2010","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.bcp.2020.114311_b0800","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0006-2952(88)90139-6","article-title":"Non-xanthine heterocycles: Activity as antagonists of A1 and A2-adenosine receptors","volume":"37","author":"Daly","year":"1988","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114311_b0805","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/jm00400a022","article-title":"Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists","volume":"31","author":"Francis","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0810","doi-asserted-by":"crossref","unstructured":"S.M. Poucher J.R. Keddie P. Singh S.M. Stoggall P.W.R. Caulkett G. Jones M.G. Collis The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist 115 (1995) 1096\u20131102.","DOI":"10.1111\/j.1476-5381.1995.tb15923.x"},{"key":"10.1016\/j.bcp.2020.114311_b0815","doi-asserted-by":"crossref","unstructured":"Sergio Todde Rosa Maria Moresco Pasquale Simonelli Pier Giovanni Baraldi Barbara Cacciari Giampiero Spalluto Katia Varani Angela Monopoli Mario Matarrese Assunta Carpinelli Fulvio Magni Marzia Galli Kienle Ferruccio Fazio Design, Radiosynthesis, and Biodistribution of a New Potent and Selective Ligand for in Vivo Imaging of the Adenosine A 2A Receptor System Using Positron Emission Tomography J. Med. Chem. 43 (2000) 4359\u20134362.","DOI":"10.1021\/jm0009843"},{"key":"10.1016\/j.bcp.2020.114311_b0820","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bmcl.2006.11.083","article-title":"Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e-]-1,2,4-triazolo[1,5-c]pyrimidines","volume":"17","author":"Neustadt","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2020.114311_b0825","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-4757-5235-9_15","article-title":"Interactions of flavones and other phytochemicals with adenosine receptors","volume":"505","author":"Jacobson","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114311_b0830","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/acs.jmedchem.9b01572","article-title":"Structure-Based Optimization of Coumarin hA 3 Adenosine Receptor Antagonists","volume":"63","author":"Matos","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2020.114311_b0835","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1021\/jm980688e","article-title":"Chiral Resolution and Stereospecificity of 6-Phenyl-4-phenylethynyl- 1,4-dihydropyridines as Selective A 3 Adenosine Receptor Antagonists","volume":"42","author":"Jiang","year":"1999","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0840","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60147-7","article-title":"A2B adenosine receptor inhibition by the dihydropyridine calcium channel blocker nifedipine involves colonic fluid secretion","volume":"10","author":"Asano","year":"2020","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.bcp.2020.114311_b0845","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1021\/acs.jmedchem.0c00564","article-title":"Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A 2B Adenosine Receptor Antagonists","volume":"63","author":"Mallo-Abreu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114311_b0850","doi-asserted-by":"crossref","unstructured":"van Muijlwijk-Koezen JE, Timmerman H, IJzerman AP. The adenosine A3 receptor and its ligands.Prog Med Chem. 2001;38:61\u2013113. https:\/\/doi.org\/10.1016\/s0079-6468(08)70092-4.","DOI":"10.1016\/S0079-6468(08)70092-4"},{"issue":"5905","key":"10.1016\/j.bcp.2020.114311_b0855","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bcp.2020.114311_b0860","article-title":"Purinergic signaling: Impact of GPCR structures on rational drug design","author":"Jacobson","year":"2020","journal-title":"ChemMedChem, in press"},{"issue":"7547","key":"10.1016\/j.bcp.2020.114311_b0865","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature14287","article-title":"Two disparate ligand-binding sites in the human P2Y1 receptor","volume":"520","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"6027","key":"10.1016\/j.bcp.2020.114311_b0870","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1126\/science.1202793","article-title":"Structure of an Agonist-Bound Human A2A Adenosine Receptor","volume":"332","author":"Xu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bcp.2020.114311_b0875","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist-bound structure of the human P2Y12R receptor","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2020.114311_b0880","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-physiol-020518-114259","article-title":"ATP-Gated P2X Receptor Channels: Molecular Insights into Functional Roles","volume":"81","author":"Schmid","year":"2019","journal-title":"Annu. Rev. Physiol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220305475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220305475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:15:38Z","timestamp":1757769338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220305475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":176,"alternative-id":["S0006295220305475"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114311","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114311"}}